Slow or absent weight loss on tirzepatide is not proof that the medicine has failed. The 2026 FDA prescribing information starts Zepbound at 2.5 mg once weekly for four weeks, followed by gradual dose increases. The 2.5 mg dose is for treatment initiation, not maintenance. Approved maintenance doses for weight management are 5 mg, 10 mg, and 15 mg once weekly, with 15 mg as the maximum recommended dose.

The most common explanations are that treatment is still being escalated, the current dose is too low, weight loss has temporarily stalled, doses have been missed, or another medicine or health condition is affecting progress.

Do not increase your dose or take extra injections without speaking to your prescriber.

Tirzepatide Weight Loss: What Is Normal?

There is no single normal weekly result with tirzepatide. Early treatment can produce little change, and weight loss can slow after an initial drop.

Situation What it may mean What to do
You started within the last few weeks You may still be in dose escalation Continue the prescribed schedule
You are taking 2.5 mg This is an initiation dose Discuss the next step with your prescriber
You have lost weight but recently stalled A weight-loss plateau can occur Track the trend and review treatment
You have type 2 diabetes Weight loss may be slower on average Discuss expectations with your clinician
You have had no meaningful trend after titration Adherence, dose, medical factors, or treatment response may need review Arrange a prescriber appointment
You have severe abdominal pain or persistent vomiting This may be a safety problem Seek urgent medical advice

Clinical trials measured tirzepatide weight loss over 72 weeks. This included the dose-escalation period and at least 52 weeks at a maintenance dose.

In adults with obesity or overweight without type 2 diabetes, average weight loss at 72 weeks was 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg. These are trial averages, not personal targets. Individual results varied.

You May Be Judging the Medication Too Early

You may be judging tirzepatide too early if you are still in the first few months or taking an initiation dose.

The FDA-approved Zepbound schedule begins with 2.5 mg weekly for four weeks. The dose can then increase by 2.5 mg, but only after at least four weeks on the current dose.

Some people also respond later. In a post-hoc analysis of the SURMOUNT-1 trial, 18% of participants had lost less than 5% of their body weight after 12 weeks. By week 24, 70% of those late responders had reached at least 5% weight loss. By week 72, 90% had done so.

Limited weight loss during the first one to three months does not prove that tirzepatide will not work for you.

You May Have Reached a Weight-Loss Plateau

A plateau can occur during tirzepatide treatment, particularly after an initial period of weight loss.

A 2025 analysis of SURMOUNT-1 and SURMOUNT-4 found that many participants eventually reached a plateau. The median time to plateau ranged from about 24 to 36 weeks, depending on starting BMI category. The analysis included people who had already lost at least 5% of their body weight, so it does not predict exactly what will happen for every patient.

A plateau can reflect a new balance between food intake, activity, body size, and medication dose. Your prescriber may recommend staying on the current dose, changing it if appropriate, or reviewing other treatment options.

Are Your Dose and Injections Consistent?

Check these points before assuming tirzepatide has failed:

  • Are you injecting once weekly?
  • Have you missed doses or taken them substantially late?
  • Are you using the exact dose prescribed?
  • Are you following the injection instructions?
  • Are you using a properly supplied and labelled product?
  • Have you recently changed pharmacies, formulations, or concentrations?

The FDA prescribing information says that a missed Zepbound dose can be taken within four days, or 96 hours. If more than four days have passed, skip the missed dose. Do not take two doses within 72 hours.

Do not take extra medication to make up for a missed dose.

How Do Diet and Activity Affect Tirzepatide Weight Loss?

Tirzepatide is prescribed alongside a reduced-calorie diet and increased physical activity. In the main weight-management trials, participants received counselling for approximately a 500-calorie daily deficit and at least 150 minutes of weekly physical activity.

You do not need a perfect diet. But appetite reduction may not create a sufficient calorie deficit if calories continue to come from:

  • Liquid calories, alcohol, sweetened coffee, or frequent snacks
  • Large portions of calorie-dense foods
  • Eating in response to boredom, stress, or social situations
  • Eating more on weekends
  • Less daily movement because of fatigue, illness, or a sedentary routine

Record food, drinks, steps, exercise, medication doses, and weekly weight for two to four weeks. Focus on the average trend instead of one weigh-in.

Can Type 2 Diabetes Slow Weight Loss?

Yes. People with type 2 diabetes lost weight in tirzepatide trials, but the average reduction was lower than in the trial involving participants without type 2 diabetes.

At 72 weeks, the FDA-reviewed studies reported:

  • Participants without type 2 diabetes lost an average of 15.0%, 19.5%, or 20.9% with 5 mg, 10 mg, or 15 mg.
  • Participants with type 2 diabetes lost an average of 12.8% with 10 mg and 14.7% with 15 mg.

These figures are averages, not individual targets. The FDA label also reports weight reduction across different ages, sexes, baseline BMIs, and glycemic-status groups.

Could Other Medicines or Health Conditions Affect Progress?

Yes. Your clinician may review:

  • Thyroid function
  • Diabetes control and insulin use
  • Sleep quality or untreated sleep apnea
  • Menopause or other hormonal changes
  • Depression, stress, or binge-eating symptoms
  • Steroids, insulin, antipsychotics, or other medicines associated with weight gain
  • Constipation, fluid retention, or another condition affecting the scale

Do not stop prescribed medicines on your own. Ask your prescriber whether your medicines, diagnoses, or recent health changes could be affecting your weight.

When Should You Contact Your Prescriber?

Arrange a treatment review if:

  1. You have completed dose escalation but have no meaningful downward weight trend.
  2. You have taken the prescribed maintenance dose consistently, but your appetite, waist measurement, and weight have not changed.
  3. Side effects are preventing dose increases.
  4. You are unsure whether your product, concentration, injection technique, or dose is correct.
  5. You have regained weight after initially losing it.

Your clinician may review your weight trend, medication history, nutrition, activity, laboratory tests, dose tolerance, and whether another treatment approach is appropriate.

When Should You Seek Urgent Medical Help?

Seek prompt medical advice for severe or persistent vomiting or diarrhoea, especially if you cannot keep fluids down. Tirzepatide has been associated with severe gastrointestinal reactions and dehydration-related kidney injury.

Seek urgent care for persistent, severe abdominal pain, particularly if it radiates to the back, with or without vomiting. The prescribing information lists these symptoms as possible signs of pancreatitis.

What Should You Do Next?

Keep taking tirzepatide only as prescribed. Track your doses and weight trend for several weeks, then discuss the results with your prescriber if weight loss has not continued after dose escalation or if side effects are limiting treatment.